Bispecific antibodies offer advantages as therapeutic modalities, including precise targeting and increased efficacy. However, production in CHO cells can present challenges that affect COGs, such as incorrect antibody chain pairing. In this presentation we will describe bYlok®, a new technology that promotes highly efficient heavy-light chain dimerization, and show some case studies where bYlok® plus other tools in the Lonza GS® toolbox can be combined to improve bsAb expression
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center